Relapse Number of participants having recurrence after stopping · patients on HD with HCV infection
Pegylated interferon alpha‐2a showed no clear difference in relapse(recurrence after stopping) compared with standard interferon (low certainty).
1 finding from 1 review
End‐of‐treatment response · patients on HD with HCV infection
Pegylated interferon alpha‐2a may leads to higher end‐of‐treatment response compared with standard interferon (low certainty).
1 finding from 1 review
Overall survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher overall survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Progression‐free survival · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy may leads to higher progression‐free survival compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse event (flu‐like symptoms) · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (flu‐like symptoms) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Adverse effect: fatigue · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (fatigue) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Neurotoxicity · Women with advanced (Stage II‐IV) epithelial ovarian cancer who have undergone surgery
Interferon + chemotherapy showed no clear difference in adverse event (neurotoxicity) compared with chemotherapy alone (low certainty).
1 finding from 1 review
Improvement in disability grade after 4 weeks · patients with Guillain‐Barré syndrome
1 finding from 1 review
Improvement in disability grade Defined as achievement of a specified degree of improvement · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes improvement in disability grade Defined as achievement of a… compared with placebo (very low certainty).
1 finding from 1 review
Time from randomisation until recovery of unaided walking · patients with Guillain‐Barré syndrome
1 finding from 1 review
Time from randomisation until discontinuation of ventilation (for those ventilated) · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Death · patients with Guillain‐Barré syndrome
Interferon beta‐1a showed no clear difference in death compared with placebo (low certainty).
1 finding from 1 review
Death or disability after 12 months · patients with Guillain‐Barré syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with 1 or more serious adverse events · patients with Guillain‐Barré syndrome
It is very uncertain whether interferon beta‐1a changes participants with 1 or more serious adverse events compared with placebo (very low certainty).
1 finding from 1 review
Change in disability after 26 or more weeks · people with CIDP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP
Interferon beta‐1a showed no clear difference in participants who completed the study and did not restart IVIg… compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events · people with CIDP
Interferon beta‐1a showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
1‐year mortality · previously untreated patients with mRCC
Interferon‐α alone probably leads to higher 1‐year mortality compared with standard targeted therapies (sunitinib or temsirolimus) (moderate certainty).
1 finding from 1 review
QoL · previously untreated patients with mRCC
5 findings from 1 review
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
no estimate extracted
1 study · 730 participants
Low
Show 2 more findings
Adverse events (grade ≥ 3) · previously untreated patients with mRCC
Interferon‐α alone may leads to higher adverse events (grade ≥ 3) compared with standard targeted therapies (sunitinib or temsirolimus) (low certainty).
1 finding from 1 review